Faruqi and Faruqui, LLP Logo
Share this page

Akari Therapeutics, Plc (AKTX)

NASDAQ:AKTX

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akari Therapeutics, Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX).

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on May 11, 2017, Akari filed a Form 6-K with the Securities and Exchange Commission announcing that Akari has established an ad hoc special committee to review the involvement of Company personnel regarding a report issued on April 26, 2017 by Edison Investment Research Inc., an investment research and advisory company. Furthermore, the Form 6-K disclosed that Dr. Gur Roshwalb, the Company’s Chief Executive Officer, has been placed on administrative leave while the review is pending.

As a result, the price of Akari’s American Depositary Receipts (“ADRs”) declined significantly, causing harm to investors.

If you invested in Akari ADRs and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Akari Therapeutics, Plc (AKTX)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 05/12/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.